Both in Pharmaceuticals
Upstream Bio vs Entrada Therapeutics
Over the past year UPB returned −86.4% and TRDA returned −33.1%; their daily moves had a correlation of 0.16.
UPB −86.4% TRDA −33.1%Growth of $1, one year, split-adjusted
| Metric | UPB | TRDA |
|---|---|---|
| Price | $3.41 | $4.54 |
| Market cap | $186.8M | $176.6M |
| Today | +4.28% | +3.07% |
| 1 month | −32.3% | −20.2% |
| 6 months | −63.7% | −68.7% |
| Year to date | −87.4% | −55.9% |
| 1 year | −85.9% | −34.2% |
| Revenue growth (YoY) | −17.5% | −53.9% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −5136.1% | −4762.0% |
| P/E (TTM) | — | — |
| Price / sales | 59.1× | 37.7× |
| Net cash | $261.3M | $223.0M |
| Dividend yield | — | — |
| Volatility (60d) | 83.4% | 79.5% |
| Short % of float | 13.2% | 13.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).